Effect of combined fluoroquinolone and azole use on QT prolongation in hematology patients

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 3, 2013, Pages 1121-1127

  Zeuli, John D ^a   Wilson, John W ^a   Estes, Lynn L ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; FLUCONAZOLE; LEVOFLOXACIN; MAGNESIUM; POSACONAZOLE; VORICONAZOLE;

ADULT; ARTICLE; DRUG EFFECT; DRUG USE; ELECTROCARDIOGRAM; FEMALE; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOLOGIC MALIGNANCY; HEMODIALYSIS; HOSPITAL PATIENT; HUMAN; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT;

ADULT; AGED; ANTIFUNGAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; FLUCONAZOLE; HEMATOLOGIC NEOPLASMS; HUMANS; HYPOKALEMIA; LONG QT SYNDROME; MALE; MIDDLE AGED; MYCOSES; OFLOXACIN; PYRIMIDINES; RISK FACTORS; TORSADES DE POINTES; TRIAZOLES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84874099261     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00958-12     Document Type: Article

References (29)

1. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D'Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foa R, Del Favero A. 2005. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N. Engl. J. Med. 353:977-987.
2. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D. 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348 -359.
3. Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, Stuart N, Rea D, Bower M, Fernando I, Huddart R, Gollins S, Stanley A. 2005. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N. Engl. J. Med. 353:988 -998.
4. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, Shadduck RK, Shea TC, Stiff P, Friedman DJ, Powderly WG, Silber JL, Horowitz H, Lichtin A, Wolff SN, Mangan KF, Silver SM, Weisdorf D, Ho WG, GilbertG, Buell D. 1992. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N. Engl. J. Med. 326:845- 851.
5. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S. 2007. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356:335- 347.
6. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, the Infectious Diseases Society of America. 2011. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 52: e56 - e93.
7. Segal BH, Freifeld AG, Baden LR, Brown AE, Casper C, Dubberke E, Gelfand M, Greene JN, Ison MG, Ito JI, Karp JE, Kaul DR, King E, MacKler E, Marcucci G, Montoya JG, Engemann AM, Rolston K, The AS. 2008. Prevention and treatment of cancer-related infections. J. Natl. Compr. Canc. Netw. 6:122-174.
8. Owens RC Jr, Nolin TD. 2006. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin. Infect. Dis. 43:1603-1611.
9. Simko J, Csilek A, Karaszi J, Lorincz I. 2008. Proarrhythmic potential of antimicrobial agents. Infection 36:194 -206.
10. Woosley RL. 2008.QTdrug lists by risk groups. AZCERT, Oro Valley, AZ. http://www.azcert.org/medical-pros/drug-lists/drug-lists.cfm.
11. Alkan Y, Haefeli WE, Burhenne J, Stein J, Yaniv I, Shalit I. 2004. Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration-dependent adverse effect. Clin. Infect. Dis. 39:e49-e52. doi:10.1086/423275.
12. Bertino JJS, Owens JRC, Carnes TD, Iannini PB. 2002. Gatifloxacinassociated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors. Clin. Infect. Dis. 34:861- 863.
13. Khazan M, Mathis AS. 2002. Probable case of torsades de pointes induced by fluconazole. Pharmacotherapy 22:1632-1637.
14. Lannini PB, Circiumaru I. 2001. Gatifloxacin-induced QTc prolongation and ventricular tachycardia. Pharmacotherapy 21:361-362.
15. Owens RC Jr. 2001. Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes. Pharmacotherapy 21: 301-319.
16. Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F. 2010. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the USFDAAdverse Event Reporting System. Drug Saf. 33:303- 314.
17. Tatetsu H, Asou N, Nakamura M, Hanaoka N, Matsuno F, Horikawa K, Mitsuya H. 2006. Torsades de pointes upon fluconazole administration in a patient with acute myeloblastic leukemia. Am. J. Hematol. 81:366 -369.
18. Tholakanahalli VN, Potti A, Hanley JF, Merliss AD. 2001. Fluconazoleinduced torsade de pointes. Ann. Pharmacother. 35:432- 434.
19. Wassmann S, Nickenig G, Bohm M. 1999. Long QT syndrome and torsade de pointes in a patient receiving fluconazole. Ann. Intern. Med. 131:797.
20. De Bruin ML, Langendijk PN, Koopmans RP, Wilde AA, Leufkens HG, Hoes AW. 2007. In-hospital cardiac arrest is associated with use of nonantiarrhythmic QTc-prolonging drugs. Br. J. Clin. Pharmacol. 63:216- 223.
21. Group I. E. W. 12 May 2005, posting date. The clinical evaluation of QT/QTC interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs E14. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/ E14/E14-Guideline.pdf.
22. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, Vicentini A, Spazzolini C, Nastoli J, Bottelli G, Folli R, Cappelletti D. 2003. Risk stratification in the long-QT syndrome. N. Engl. J. Med. 348: 1866-1874.
23. Roden DM, Woosley RL, Primm RK. 1986. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am. Heart J. 111:1088 -1093.
24. Woosley RL, Chen Y, Freiman JP, Gillis RA. 1993. Mechanism of the cardiotoxic actions of terfenadine. JAMA 269:1532-1536.
25. Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. 2010. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J. Am. Coll. Cardiol. 55:934 -947.
26. Roden DM. 2004. Drug-induced prolongation of the QT interval. N. Engl. J. Med. 350:1013-1022.
27. Kannankeril PJ, Roden DM. 2007. Drug-induced long QT and torsade de pointes: recent advances. Curr. Opin. Cardiol. 22:39-43.
28. Hunter JD, Sharma P, Rathi S. 2008. Long QT syndrome. Contin. Educ. Anaesth. Crit. Care Pain 8:67-70.
29. Roden DM. 2006. Long QT syndrome: reduced repolarization reserve and the genetic link. J. Intern. Med. 259:59-69.